Petros Pharmaceuticals Inc Total Liabilities
Petros Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) has total liabilities worth $27.19 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See PTPI days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Petros Pharmaceuticals Inc (2018–2024)
Total liabilities of Petros Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Petros Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Petros Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Petros Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boostheat
PA:ALBOO
|
France | €3.20 Million |
|
Headlam Group
LSE:HEAD
|
UK | GBX244.70 Million |
|
Chill Brands Group PLC
LSE:CHLL
|
UK | GBX3.37 Million |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
Germany | €8.41 Billion |
|
Greenroc Mining PLC
LSE:GROC
|
UK | GBX2.85 Million |
|
ADVANCED INF SERV(ADVANC)
STU:NVAA
|
Belgium | €349.41 Billion |
|
CAP-XX Limited
LSE:CPX
|
UK | GBX3.74 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Petros Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Petros Pharmaceuticals Inc.
Liquidity & Leverage Metrics
Petros Pharmaceuticals Inc Total Liabilities Ratios Explained
Petros Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Petros Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Petros Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.10 Million | -15.07% |
| 2023-12-31 | $21.32 Million | +35.61% |
| 2022-12-31 | $15.72 Million | -50.64% |
| 2021-12-31 | $31.85 Million | -39.21% |
| 2020-12-31 | $52.38 Million | +4.05% |
| 2019-12-31 | $50.35 Million | -26.57% |
| 2018-12-31 | $68.57 Million | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.